[Tizanidine in the treatment of acute withdrawal symptoms in heroin dependent patients].
One of the treatment alternative of withdrawal symptoms of patients suffering from opiate dependence is to apply the clonidine in combination or itself. This remedy is not in commercial trade in our country. It is expectable according to the recent data analysing the effects of the alfa2 adreneregic agonist tizanidine that tizanidine has the similar protective effect as clonidine with the resembling target point. Based on this theory a research was done, in the course of which the i.v. heroin users who presented themselves at the Drug Outpatient Department of Buda between 1.10.1998-8.01.1999. were divided into two groups. The groups had got the usual detoxification treatment, but in the experimental group tizanidine were given in 3 x 8 mg/day dose too. Sixteen patients were in the tizanidine group, 10 patients were in the control group. The patients estimated the intensity of 7 symptoms of withdrawal (sweating, nervousness, insomnia, tremor, diarrhoea, muscle pain, drug craving) on a subjective scale day by day. The analysis showed that the tizanidine treatment decreased the intensity of the withdrawal symptoms in every symptom type examined. The ten days long acute withdrawal period were accomplished by all of the patients, but in the short course of the following (mean 9 and 11 weeks in the treated and the control groups respectively) there were three relapses in each group (3/16 in the treated and 3/10 in the control).
Sós
I
I
Országos Alkohológiai és Addiktológiai Intézet, Budapest.
Kiss
N
N
Csorba
J
J
Gerevich
J
J
D000208:Acute Disease; D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D016022:Case-Control Studies; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D003932:Heroin / Q000008:administration & dosage / Q000009:adverse effects*; D006556:Heroin Dependence; D006801:Humans; D008297:Male; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D000700:Analgesics; D000927:Anticonvulsants; D009125:Muscle Relaxants, Central; D009294:Narcotics; C023754:tizanidine; D003932:Heroin; D003000:Clonidine